

SARS-CoV-2 and Bioactive Compounds: A Literature Review

ABSTRACT

Aims: This literature review seeks to summarize the role of some bioactive compounds during COVID-19.

Methodology: A PubMed literature review was conducted using combinations of the key words “natural products,” “nutrients,” and “COVID-19.” All study types were considered and relevant articles were utilized for this review.

Results: COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, and dietary factors can influence the transmission and/or progression of the disease. Vitamin C, vitamin D, zinc, turmeric, ginger and propolis have antiviral, anti-inflammatory and immunomodulatory activity and can be a great ally in the fight against the new coronavirus.

Conclusion: Despite the diverse scientific evidence that points to the benefits of bioactive compounds in the treatment of COVID-19, more randomized and controlled studies are needed to determine the ideal doses of consumption or supplementation and the times when this administration is safe.

Keywords: COVID-19, health, natural products, nutrients.

You don't need to write "literature review" everywhere, just the heading is enough. After that make a close knitted abstract of this paper. How often do people use bioactive compounds or are those from nature or artificial? How efficient are those? In the methodology section, describe the experiments.

1. INTRODUCTION

With the arrival of COVID-19, many existing global health problems became more evident. In addition to energy shortages, climate change and environmental degradation, food insecurity is increasingly visible. Although all people have the right to access food in adequate quantity and quality, the pandemic had a significant impact on this process. According to the Eat Report (2020), 820 million people still do not have access to food in adequate quantities and qualities. It is also known that both malnutrition and obesity can worsen the clinical outcome of patients with COVID-19. Regarding food quality, individuals decreased their consumption of healthy foods and increased their consumption of ultra-processed foods. Such changes in food consumption negatively impact the health of individuals [1].

The consumption of healthy foods, rich in vitamins, minerals and bioactive compounds that can help in the functioning of the immune system [2]. In general, viral infection increases oxidative stress and inflammatory cytokines which can cause cell malfunction [3]. On the other hand, the consumption of foods rich in bioactive compounds can strengthen physiological functions, thus allowing a better response of the immune system to the disease, that can play a role in preventing and/or treating COVID-19 [4].

This review focuses on the mechanisms of action of bioactive compounds can affect the proliferation and spread of the COVID-19 virus. To this, a literature search was performed using PubMed from database inception to May 2023. Articles written in English, spanishportuguese are included. The search terms included "natural products and COVID-19"; "nutrients and COVID-19". (delete these sentences, it's not required)

There should be a method paragraph and discussion section in this paper. Incorporate following paragraphs in the discussion section.

DESCRIBE SOME EXPERIMENTAL METHODS OVER HERE

DISCUSSION

2.1 Vitamin C

In general, viral infection increases oxidative stress and inflammatory cytokines which can cause cell malfunction [3]. In order to mitigate the infection scenario, there is a greater metabolic demand for vitamin C [5]. Thus, the ingestion of substances such as ascorbic acid, if used regularly and in adequate doses, can help the immune system efficiently [6, 7]. Supplementation has the potential to treat respiratory and systemic infections, and may relieve chest pain, fever and chills, in addition to decreasing the average recovery time from flu syndrome [8, 9].

Hypotheses about the use of vitamin C and its potential in mitigating the symptoms of patients with COVID-19 are being investigated, not only for mild conditions, but also in patients with critical conditions [10]. In consideration of the development of possible lung lesions in viral infections such as SARS-CoV-2, antioxidants play a role in managing these conditions by protecting important structural components of cells [7]. Thus, the adequacy of the consumption of food sources rich in Vitamin C and, in some cases, supplements with this micronutrient can assist in maintaining health, in addition to participating as adjuvant therapy in infections by viral diseases [11, 12].

In severe cases, intravenous administration of vitamin C has also been studied and indicated [13]. A recent study proposed a protocol for the administration of vitamin C to patients with COVID-19. This protocol includes administration in a single or divided dose in 2 to 4 times a day from 0.2 to 0.5 g/kg of body weight per day of vitamin C, and in more severe patients the amount can be increased to 0.4 to 1 g/kg of body weight per day of vitamin C. When the dose administered is greater than 50 g per day, it is recommended that vitamin C be offered through the central venous access. The recommended infusion rate is 0.25 to 0.5 g/min, between 1 to 4 hours depending on the dose. In addition, calcium and/or magnesium supplementation is recommended, as vitamin C can interfere with the levels of these minerals. Through the enteral route, it is suggested to administer 220 mg zinc sulfate (50 mg elemental zinc) daily, 400 mg thiamine daily, 6 mg melatonin daily and 1600 IU vitamin E every other day. In addition, it should be offered from 5,000 to 10,000 IU of vitamin D a day, with the objective of reaching serum 25-OH levels between 80 to 90 nmol/L. The same authors report that up to 100 g daily vitamin C is safe, as long as the patient's evaluation is accompanied by laboratory tests, such as blood count, kidney function, iron, ferritin, electrolytes [14].

2.2 Vitamin D

Vitamin D can act by preventing an uncontrolled immune system function in the face of the pathology triggered by SARS-CoV-2, which is associated with the release of pro-inflammatory cytokines within the cells of the host [11, 15]. In addition, calcitriol (1,25-dihydroxyvitamin D3) plays a modulating role in the expression Angiotensin-Converting Enzymes 1 (ACE1) and 2 (ACE2), thus increasing protection against lung injury [16, 17].

Therefore, the decrease in ACE2 activity in the lungs improves the health outcomes of patients with the new coronavirus [18]. CRP, an inflammatory marker in response to cytokines, was found reduced in patients with high levels from vitamin D, according to the University of Cincinnati [19]. Another factor of great relevance was the appearance of clots in patients who presented with severe COVID-19, where high serum concentrations of D-dimer would be associated with a high prothrombotic prevalence in patients in ICU [20].

2.3 Zinc

Regarding minerals, zinc is a well discussed microelement in the current literature, which directly affects the immune system. It is known that the elderly is more likely to have zinc deficiency, being a trigger for the development of pneumonia, since the risk of the organism is increased when contracting entero-viral pathogens and bacteria that can cause intestinal dysfunction and decrease the absorption of nutrients, further leading to the compromise of the mineral in the body [21].

The implications for the use of zinc in patients with COVID-19 are diverse. First, zinc positively affects innate and acquired immunity [22]. Second, it is known that zinc has a potent antiviral action against several types of viruses, such as single strand positive sense RNA virus (+) ssRNA, being extremely important in the treatment of viral infections [4]. In the current scenario of COVID-19, zinc plays an important role in inhibiting the RNA-dependent RNA Polymerase (RdRp), present in the virus, and its ionophores act by blocking the replication of SARS-CoV-2 within the cell [23]. Third, according to Mayor-Ibargüen et al. (2020) [24], low levels of zinc have been observed in the most severe cases of COVID-19. IL-6 has also been linked to severe lung injury. IL-6 (-174G/C) polymorphism carriers have higher IL-6 values in addition to changes in zinc homeostasis [25]. Finally, it has found that zinc might inhibit ACE2 activity [21], in addition to potentiating the action of antiviral drugs [22].

2.4 Curcumin

More than 300 clinical trials have shown benefits of curcumin against inflammatory diseases, metabolic diseases, liver disease and cancers. In addition, studies show the effectiveness of this bioactive compound against different viruses, such as the human immunodeficiency virus (HIV) [26], Chikungunya and Zika virus [27], which can be an alternative in the treatment of COVID-19 [28].

The effects of curcumin in combating viral infections occur due to its ability to prevent the virus from entering the cell [29] in addition to inhibiting the oxidative stress caused by inflammation [30]. Specifically, in COVID-19, curcumin can bind to the receptor-binding domain of the viral spike protein, thereby preventing the binding of that protein to the ACE2 receptor site and, consequently, prevents replication of the virus [31]. Furthermore, in pulmonary inflammation, evidence shows that turmeric can decrease the expression of pro-inflammatory cytokines [28] and acts as an antithrombotic [29, 32].

2.5Ginger

Studies validate that the compounds found in ginger are satisfactory for the relief of symptoms of inflammatory diseases, positively interfering in the immune response, in addition to having antipyretic, analgesic, antidiabetic, anticancer, antioxidant and anti-inflammatory effects [33]. Although it does not directly affect leukocyte activities; its action contributes to the strengthening of immunity. It is a source of the phytochemical gingerol, which acts to reduce the secretion of IL-1, IL-12 and TNF- α . Shogaol, another potent phytochemical, is able to inhibit the production of prostaglandin E2 and pro-inflammatory cytokines such as IL-1 β and TNF- α [34, 35].

In the composition of ginger essential oil, its constituents are used pharmacologically in the treatment of chronic inflammation, pulmonary obstruction, asthma and rheumatoid arthritis. In addition, it has the ability to inhibit the synthesis of prostaglandins and platelet aggregation, which, as previously stated, is a clinical condition frequently seen in patients with COVID-19 [36, 37].

A study of mice treated with ginger extract, the results suggest that the volatile oil of ginger influences the cell-mediated immune response and the nonspecific proliferation of T lymphocytes, and may have beneficial effects in various clinical conditions, such as inflammation [38]. In addition, ginger influences the expression of antioxidant enzymes [39, 40]. Furthermore, ginger also has anti fibrotic properties – in studies with animal models, pulmonary fibrosis was reduced as well as oxidative stress and inflammatory status [41].

2.6Propolis

Propolis has been used by medicine for many years for the treatment of various diseases due to its wide therapeutic properties as antimicrobial, antioxidant and antiviral activity in the human body [42]. Its composition is defined by several factors such as region, climate, seasons and environmental conditions. However, most of the bioactive compounds present in propolis are from the class of polyphenols, including flavonoids, tannins, stilbenes and phenolic acids [43].

In clinical studies, propolis has demonstrated antiviral activity in different types of viruses such as HSV-1, HSV-2, influenza virus types A and B, parainfluenza virus, adenovirus, HIV, among others [44]. In addition, the flavonoids present in several types of propolis (quercetin, luteolin and kaempferol) can develop an anti-inflammatory and antiviral action, whereas those found in red propolis can act as an anti-inflammatory and hyperthermia reducing agent, being able to exert a beneficial action in treatment by COVID-19 [39]. In addition, propolis strengthens the immune system by increasing the activity of NK cells that fight tumor cells and develops antimicrobial action against Gram-positive bacteria [45]. The effects on the immune system are also associated with a reduction in prostaglandins, leukotrienes and pro-cytokines, inflammatory with increased IL-10 [42].

Studies with propolis and coronavirus are scarce. One of the main mechanisms by which propolis acts as an antiviral involves its potential effect of inhibiting the entry of the virus into cells, thus decreasing its replication [44]. The caffeic and p-coumaric acids found in the propolis extract can bind to HSPA5 present on the cell surface, preventing the viral protein from binding to that location. This effect can also be developed by Caffeic Acid Phenethyl Ester (CAPE), which in addition to suppressing lipoxygenases, inhibits the production of leukotrienes by macrophages [46]. In addition, CAPE is considered a RAC/CDC42-activated kinase 1 (PAK1) blocker, capable of decreasing the expression of the PAK1 pathway, thus decreasing pulmonary fibrosis caused by COVID-19 [47].

Thirty years ago, Debiaggi et al. (1990) [48] conducted a study with human coronavirus OC43 and demonstrated that chrysin and kaempferol inhibited viral replication. Another flavonoid found in propolis that has an important effect is quercetin. In an in vitro study, Nguyen et al. (2012) [49], showed that epigallocatechin gallate and quercetin inhibit the SARS-CoV main protease 3CLpro, the main protease responsible for virus replication. Another in vitro study also showed that quercetin inhibits both of the SARS-CoV proteases, 3CLpro and PLpro, in addition to inhibiting 3CLpro protease in cases of Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) [50]. According to Nabirovichkin et al. (2020) [51], a quercetin modulates the cellular Unfolded Protein Response (UPR), a pathway that, when activated, increases the expression of chaperones located in the endoplasmic reticulum and is used at different times in the replication of the virus during infection.

The viral spike connects with the receptor protein so that the virus's genetic material gets deposited in the cell. The preferential receptor by SARS-CoV-2 is called ACE-II. SARS-CoV-2 spike protein is estimated to have a strong binding affinity to human ACE-II. So, one of the therapeutic targets is to block the ACE-II receptor, so that the virus stops infecting new cells. Looking for flavonoids in propolis extract with the ability to bind these receptors was done and showed that rutin, myricetin, quercetin, CAPE and hesperetin have a better affinity against ACE-II enzyme than natural inhibitor MLN-4760 among the evaluated compounds. It's important to notice that the smaller binding energy and K_i value, the more tightly bound the ligand is [52]. The administration of antivirals such as IFN- α , ribavirin, chloroquine phosphate and arbidol together with propolis can develop a positive recovery effect for patients infected with SARS-CoV-2 [42]. However, some people have an aversion to propolis and may develop allergies and contact dermatitis, requiring an evaluation and monitoring of patients who will receive this substance [46].

In summary, Table 1 shows the articles that were carried out using some of the bioactive compounds against COVID-19, followed by the dose or therapeutic plan, main results and mechanisms of action...these sentences should be the caption of table 1.

Table 1. Potential of bioactive compounds against COVID-19 ~~Delete this reference column.~~

| Bioactive Compounds | References | Dose/Therapeutic plan | Conclusions | Mechanism of action |
|---------------------|------------|---|---|--|
| Vitamin C | [14] | 30 – 60 g/day (with calcium and/or magnesium supplementation) | Improves in the oxygenation index. | Neutralizes free radicals preventing them from causing tissue damage and also activating the factor nuclear kappa B (NF-kB) pathway; reduction of oxidative stress and inflammatory state. |
| | [53] | 1,5 g/6h/day | Improvement in chest radiologic findings and lower mortality. | |
| | [54] | 50 mg/kg/day | Did not significantly improve organ dysfunction scores, c-reactive protein levels or vascular injury. The study itself reports that possible limitations may have interfered with the results found. One of these limitations is that the dosage of vitamin C administered, that is, 50 mg/kg every 6 hours for 96 hours, may be insufficient for the control of the sepsis associated ARDS. | |
| | [55] | 6 g intravenous infusion per 12 hr on the first day and 6 g once for 4 days | Patients with > 60 years and severe or critical disease, the risk of mortality was significantly reduced – about 20%, with higher dose vitamin C than standard therapy. For moderate cases, oxygen support status was improved for 28 patients, and 17 of them were in the high-dose vitamin C group and 11 in the standard therapy group, which represents a 28% advantage for those who received ascorbic acid. | |
| | [56] | 24 g/day | The test group showed lower mortality (6 deaths) compared to the | |

| | | | | |
|-----------|------|---|--|--|
| | | | control group (11 deaths), but showed a slight increase in total days of hospitalization (2.2 days) and no significant improvement needing invasive and non-invasive mechanical ventilation. | |
| Vitamin D | [57] | - | The hospitalized compared to non-hospitalized individuals had a significantly lower mean plasma 25 (OH) D level (18.38 ng/mL vs. 20.45 ng/mL). | Modulates the release of inflammatory chemokines and cytokines by macrophages; modulates the role in the expression Angiotensin-Converting Enzymes 1 (ACE1) and 2 (ACE2); acts controlling pathways of cell proliferation and differentiation, apoptosis and angiogenesis. |
| | [19] | - | 24% of critically ill patients were deficient in vitamin D while only 7,3% of non-critical patients were deficient, which shows a correlation between the severity of the disease and the levels of the vitamin. | |
| | [58] | Patients with levels below 50 nmol/L, supplementation of 50,000 IU twice a week until adequate levels of 25 (OH) D are reached (100-150 nmol/L) | The achievement of plasma vitamin D values is associated with a reduction in the risk of worsening and a decrease in the mortality rate. | |
| Zinc | [59] | < 50 µg/dL or > 50 µg/dL about to 8 days | Critically ill patients showed low zinc concentrations (<50µg/dL) compared to patients with mild to moderate symptoms (63.1 µg/dl). Patients who received doses less than 50 µg/dL needed more recovery time (25 days) compared to those who received doses greater than 50 µg/dL (8 days). Lower concentrations of IL-6 and CRP were also identified in these | Development of innate immunity defense cells natural killer cells (NK) and neutrophils; involved in the metabolic processes of carbohydrates and lipids, reproductive function, cardiovascular and nervous system; intrinsic role in all stages of lymphocyte and leukocyte functioning, from proliferation to maturation. |

| | | | | |
|----------|------|--|--|---|
| | | | subjects (>50 µg/dl). Increasing serum zinc levels, mortality rates fell by 7%. | |
| | [60] | 15 or 23 mg of elemental zinc every 2-4 hours | A high dose of oral zinc salt resulted in clinical recovery, improved oxygenation, and less shortness of breath among those patients. | |
| Curcumin | [61] | 160 mg of nano- curcumin capsules and placebo capsules to the control group | Expression level of IL-1β and IL-6 decreased after treatment with nano- curcumin compared with the pre- treatment state and the placebo group. 62% of patients had improvements in fever (from > 37.3°C to < 37.3°C) compared to the control placebo group, which did not obtain significant improvement. | Prevent the virus from entering the cell and also its potent action in inhibiting viral replication; inhibits oxidative stress caused by inflammation; acts under the NF-kB and mitogen activated protein kinase (MAPK) pathways, thus blocking the expression of pro-inflammatory cytokines produced in these pathways; play an anticoagulant function by inhibiting the cyclooxygenase pathway, platelet aggregation and calcium signaling pathway. |

Advices to make your career better---

1. Write the whole paper in past participle form.
2. Take care of the spacing in between words.
3. Use a single front all over the manuscript body.
4. You should re-organize the paper in a different format such as- Introduction/theory, Method, Results, Discussion, Conclusion, extra supplementary data or tables.
5. Add those two over sized table in the end or resize and make it smaller, so that it can fit with rest of the writing format.

UNDER PEER REVIEW

3. CONCLUSIONS

The present study reviewed some nutritional factors that may facilitate or hinder the multiplication of the COVID-19 virus. Some compounds, due to their antioxidant and anti-inflammatory action, contribute to the neutralization of ROS and inflammatory cytokines. Vitamin C, zinc and propolis act as antioxidants, anti-inflammatory, antiviral and are very important for the regulation of immune function. In addition to these functions, Vitamin D, curcumin and ginger have shown to have an antithrombotic effect. However, despite the benefits presented here, some points must be taken into account. First, the clinical studies presented here did not report which viral types were studied and the action of these bioactive compounds may be different for the different variants of COVID-19. Second, it is important that new studies and randomized controlled studies are carried out to determine safe and effective doses for the ingestion of these compounds, in addition to determining in which situations the use of these nutrients may or may not be indicated, according to the variants of the virus. Finally, it is very important to remember that a healthy diet is essential for the immune system to have a variety of these nutrients, bioactive compounds, proteins and microelements, which is more interesting than the ingestion of a single compound or nutrient.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

REFERENCES

1. Carvalho KP. As connections entre o sistema alimentar dominante e a COVID-19: desafios à Segurança Alimentar e Nutricional no tempo presente e apos. *Segur Aliment Nutr.* 2021;28: 1-11. DOI: 10.20396/san.v28i00.8661416.
2. de Souza LO, da Silva RG, Rodrigues DBS, Cardoso AVS, Freitas AS, Cruz BRS, et al. Food and immunity: the role of food in reducing complications caused by Covid-19. *Braz J Dev.* 2021;7(4): 38795-38805.
3. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. *PharmaNutrition.* 2020;12:100190. DOI:10.1016/j.phanu.2020.100190.
4. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. *Med Virol.* 2020;92(5): 479-490. DOI:10.1002/jmv.25707.

5. Fowler Iii, Kim C, Lepler L, Malhotra R, Debesa O, Natarajan R. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. *World J Crit Care Med.* 2017;6(1): 85-90. DOI:10.5492/wjccm.v6.i1.85.
6. Dey S, Bishayi B. Killing of *S. aureus* in murine peritoneal macrophages by ascorbic acid along with antibiotics Chloramphenicol or Ofloxacin: Correlation with inflammation. *MicrobPathog.* 2018;115: 239-250. DOI:10.1016/j.micpath.2017.12.048.
7. ColungaBiancatelli RML, Berrill M, Marik PE. The antiviral properties of vitamin C. *Expert Rev Anti Infect Ther.* 2020;18(2): 99-101. DOI:10.1080/14787210.2020.1706483.
8. Carr AC, Maggini S. Vitamin C and Immune Function. *Nutrients.* 2017;9(11):1211. DOI:10.3390/nu9111211.
9. Ran L, Zhao W, Wang J, Wang H, Zhao Y, Tseng Y, et al. Extra Dose of Vitamin C Based on a Daily Supplementation Shortens the Common Cold: A Meta-Analysis of 9 Randomized Controlled Trials. *Biomed Res Int.* 2018;1837634. DOI:10.1155/2018/1837634.
10. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. *Crit Care.* 2020;24(1):133. DOI:10.1186/s13054-020-02851-4.
11. Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? *BMJ Nutr Prev Health.* 2020;3(1):100-105. DOI:10.1136/bmjnp-2020-000071.
12. Simonson W. Vitamin C and coronavirus. *Geriatric Nurses.* 2020;41(3):331-332. DOI:10.1016/j.gerinurse.2020.05.002.
13. de Melo AF, Homem-de-Mello M. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. *Crit Care.* 2020;24(1):500. DOI:10.1186/s13054-020-03228-3.
14. Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, et al. Two known therapies could be useful as adjuvant therapy in critical patients infected **by COVID-**

19. Rev Esp AnestesiolReanim (Engl Ed). 2021;67(5):245-252. DOI:10.1016/j.redar.2020.03.004. **Where is author's name?**

15. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199-1207. DOI:10.1056/NEJMoa2001316.

16. Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. *Nature*. 2020;583(7815):282-285. DOI:10.1038/s41586-020-2169-0.

17. Carter SJ, Baranaukas MN, Fly AD. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic. *Obesity (Silver Spring)*. 2020;28(7):1176-1177. DOI:10.1002/oby.22838.

18. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res*. 2020;32(7):1195-1198. DOI:10.1007/s40520-020-01570-8.

19. Yisak H, Ewunetei A, Kefale B, Mamuye M, Teshome F, Ambaw B, et al. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review. *Risk Management Healthcare Policy*. 2021;14: 31-38. DOI:10.2147/RMHP.S291584.

20. Tian Y, Rong L. Letter: Covid-19, and vitamin D. Authors' reply. *Aliment Pharmacol Ther*. 2020;51(10): 995-996. DOI:10.1111/apt.15764.

21. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko, SI. Zinc and respiratory tract infections: Perspectives for COVID- 19 (Review). *Int J Mol Med*. 2020;46(1): 17-26. DOI:10.3892/ijmm.2020.4575.

22. Rahman MT, Idid SZ. Can Zn Be a Critical Element in COVID-19 Treatment? *Biol Trace Elem Res*. 2021;199(2): 550-558. DOI:10.1007/s12011-020-02194-9.

23. Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? *Med Hypotheses*. 2020;142:109815. DOI:10.1016/j.mehy.2020.109815.

- 24.** Mayor-Ibarguren A, Busca-Arenzana C, Robles-Marhuenda Á. A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19. *Front Immunol.* 2020;11: 1736. DOI:10.3389/fimmu.2020.01736.
- 25.** Kirtipal N, Bharadwaj S. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans. *J Biomol Struct Dyn.* 2021;39(12):4563-4565. DOI.org/10.1080/07391102.2020.1776640.
- 26.** Prasad S, Tyagi AK. Curcumin and its analogues: a potential natural compound against HIV infection and AIDS. *Food Funct.* 2015;6(11):3412-9. DOI:10.1039/c5fo00485c.
- 27.** Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M. Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. *Antiviral Res.* 2017;142:148-157. DOI:10.1016/j.antiviral.2017.03.014.
- 28.** Zahedipour F, Hosseini SA, Sathyapalan T, Majeed M, Jamialahmadi T, Al-Rasadi K, et al. Potential effects of curcumin in the treatment of COVID-19 infection. *Phytother Res.* 2020;34(11): 2911-2920. DOI:10.1002/ptr.6738.
- 29.** Roy A, Sarkar B, Celik C, Ghosh A, Basu U, Jana M. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19? *Phytother Res.* 2020;34(10): 2425-2428. DOI:10.1002/ptr.6766.
- 30.** Marchi JP, Tedesco L, Melo AC. Curcuma longa L. o açafrão da terra, e seus benefícios medicinais. *ArqCiencSaúde UNIPAR.* 2016;20(3): 189-194.
- 31.** Manoharan Y, Haridas V, Vasanthakumar KC, Muthu S, Thavoorullah FF, Shetty P. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management. *Indian J Clin Biochem.* 2020;35(3): 373-375. DOI.org/10.1007/s12291-020-00902-9.
- 32.** Rocha FAC, de Assis MR. Curcumin as a potential treatment for COVID-19. *Phytother Res.* 2020;34(9):2085-2087. DOI:10.1002/ptr.6745.

- 33.** Anh NH, Kim SJ, Long NP. Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials. *Nutrients*. 2020;12(1):157. DOI:10.3390/nu12010157.
- 34.** Vieira NA, Tomiotto FN, Melo GP, Manchope MF, Lima NR, Oliveira GG, et al. The anti-inflammatory effect of ginger is possible via signaling. *SeminaCiênc Biol Saúde*. 2014; 35(1):149-62. DOI.org/10.5433/1679-0367.2014v35n1p149.
- 35.** Nagendrachi KL, Manasa D, Srinivas P, Sowbhagya HB. Enzyme-assisted extraction of bioactive compounds from ginger (*Zingiber officinale* Roscoe). *Food Chem*. 2013;139(1-4): 509-14. DOI:10.1016/j.foodchem.2013.01.099.
- 36.** Dabague ICM, Deschamps C, Mógor AF, Scheer AP, Côcco L. Essential oil yield and composition of ginger (*Zingiber officinale* Roscoe) rhizomes after different drying periods. *Rev bras plantas med*. 2011;13(1): 79-84. DOI.org/10.1590/S1516-05722011000100012.
- 37.** Shah A, Krishnamurthy R. Swine flu and its herbal remedies. *Int J Eng Sci*. 2013;2(2): 68–78.
- 38.** Zhou HL, Deng YM, Xie QM. The modulatory effects of the volatile oil of ginger on the cellular immune response in vitro and in vivo in mice. *J Ethnopharmacol*. 20016;105(1-2): 301-5. DOI:10.1016/j.jep.2005.10.022.
- 39.** Silva FGC, Borges ALTF, Oliveira JVL, Prata APN, Porto ICCM, Almeida CAC, et al. Foods, nutraceuticals and medicinal plants used as complementary practice in facing up the coronavirus (covid-19) symptoms: a review. *Scielo preprints [Preprint]*. 2020.
- 40.** de Souza J, Sarturi L, de Abreu AR, Araújo de Sousa T, Geron VLMG. Breve relatosobreosefeitosterapêuticos do gengibre (*Zingiber officinale* Roscoe). *Rev Cient da Fac Educ e MeioAmbiente*. 2019;10(1): 44-53. DOI:10.31072/rcf.v10iedesp.785.
- 41.** Thota SM, Balan V, Sivaramakrishnan V. Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19. *Phytother Res*. 2020;34(12): 3148-3167. DOI:10.1002/ptr.6794.

- 42.** Mohamed S. Propolis anti-viral activity towards COVID-19: is it effective? Research gate [Preprint]. 2020.
- 43.** Güler HI, Tatar G, Yildiz O et al. An investigation of ethanolic propolis extracts: Their potential inhibitor properties against ACE-II receptors for COVID-19 treatment by Molecular Docking Study. Science Open Preprints [Preprint]. 2020.
- 44.** Bachevski D, Damevska K, Simeonovski V, Dimova M. Back to the basics: Propolis and COVID-19. *Dermatol Ther.* 2020;33(4):e13780. DOI:10.1111/dth.13780.
- 45.** Almeida EC, Menezes H. Atividade anti-inflamatória de extratos de própolis: a review. *J. Venom. Anim. Toxins.* 2002;8(2):191-212. DOI.org/10.1590/S0104-79302002000200002.
- 46.** Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. *J Biomol Struct Dyn.* 2020;39(9): 3194-3203. DOI:10.1080/07391102.2020.1761881.
- 47.** Maruta H; He H. PAK1-blockers: Potential Therapeutics against COVID-19. *Med Drug Discov.* 2020;6:100039. DOI:10.1016/j.medidd.2020.100039.
- 48.** Debiaggi M, Tateo F, Pagani L, Luini M, Romero E. Effects of propolis flavonoids on virus infectivity and replication. *Microbiologica.* 1990;13(3):207-213.
- 49.** Nguyen TT, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW, et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in *Pichia pastoris*. *Biotechnol Lett.* 2012;34(5): 831-8. DOI:10.1007/s10529-011-0845-8.
- 50.** Park JY, Yuk HJ, Ryu HW, Lim SH, Kim KS, Park KH, et al. Evaluation of polyphenols from *Broussonetiapapyrifera* as coronavirus protease inhibitors. *J Enzyme Inhib Med Chem.* 2017;32(1): 504-515. DOI:10.1080/14756366.2016.1265519.
- 51.** Nabirotkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. Preprints. 2020. DOI: 10.20944/preprints202003.0302.v1.

- 52.** Guler HI, Tatar G, Yildiz O, Belduz AO, Kolayli S. An investigation of ethanolic propolis extracts: Their potential inhibitor properties against ACE-II receptors for COVID-19 treatment by Molecular Docking Study. *Arch Microbiol.* 2021;203(6):3557-3564. DOI:10.1007/s00203-021-02351-1.
- 53.** Kim WY, Jo EJ, Eom JS, Mok J, Kim MH, Kim KU, et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. *J Crit Care.* 2018;47: 211-218. DOI:10.1016/j.jcrc.2018.07.004.
- 54.** Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Trial. *Randomized Clinical Trials. JAMA.* 2019;322(13):1261-1270. DOI:10.1001/jama.2019.11825.
- 55.** Gao D, Xu M, Wang G, Lv J, Ma X, Guo Y. The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study. *Aging (Albany NY).* 2021;13(5): 7020-7034. DOI: 10.18632/aging.202557.
- 56.** Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. *Ann Intensive Care.* 2021;11(1):5. DOI: 10.1186/s13613-020-00792-3.
- 57.** Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS J.* 2020;287(17):3693-3702. DOI:10.1111/febs.15495.
- 58.** Ebadi M, Montano-Loza AJ. 2020. Perspective: improving vitamin D status in the management of COVID-19. *Eur J Clin Nutr* 74(6): 856-859. DOI:10.1038/s41430-020-0661-0.
- 59.** Vogel-González M, Talló-Parra M, Herrera-Fernández V, Pérez-Vilaró G, Chillón M, Nogués X, et al. Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. *Nutrients.* 2021;13(2), 562. DOI.org/10.3390/nu13020562.
- 60.** Finzi E. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients. *Int J Infect Dis.* 2020;99:307-309. DOI:10.1016/j.ijid.2020.06.006.

61. Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, ZiyaGencer M, Ammari A, Sadeghi A, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. *Int Immunopharmacol.* 2020;89(Pt B):107088. DOI: 10.1016/j.intimp.2020.107088.

UNDER PEER REVIEW